Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for RNA Export Inhibitor and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALY/ALYREF drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALY/ALYREF Full-Length Recombinant Protein – HEK293 expressed, high purity (>95%), endotoxin <1EU/ug, sequence verified. | View ALY/ALYREF Products |
| Domain Antigen | ALY/ALYREF RBD Domain (RNA Binding Domain, covering RRM motifs) – refolded or soluble expression, high purity (>90%), for binding specificity assays. | View ALY/ALYREF Products |
| Gene Delivery | ALY/ALYREF Promise-ORF Lentivirus – full-length ORF for stable cell line construction, CMV promoter, puromycin selection. | View ALY/ALYREF Products |
| Validator | ALY/ALYREF siRNA Set (3 targets + NC) – sequence verified, >85% knockdown efficiency guarantee. | View ALY/ALYREF Products |
| Benchmark Ab | Anti-ALYREF Recombinant Biosimilar Control – positive control for western blot and validation assays. | View ALY/ALYREF Products |
| Interaction Partner | NXF1 (TAP) – nuclear RNA export factor 1, critical binding partner for functional assays, high purity. | View NXF1 Products |
| Complex Member | THOC5 (CIP29) – THO complex subunit 5, TREX complex component for co-expression studies. | View THOC5 Products |
| Associated Helicase | DDX39B (UAP56) – DEAD-box helicase, TREX component for RNA unwinding/export complex assays. | View DDX39B Products |
| Related Target | eIF4A3 – core component of the Exon Junction Complex (EJC), critical ALYREF interaction partner. | View EIF4A3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RNA-Binding Specificity (RBD/RRM domains) | Domain-specific truncations (RBD1/RBD2) with verified folding and sequence-confirmed RNA-binding motifs. |
| Nuclear Export Complex Reconstitution | NXF1 co-available; both proteins HEK293 expressed for native mammalian folding and PTMs. |
| Protein-Protein Interaction (PPI) Screening | High-purity (>95%) recombinant ALYREF proteins, structurally intact for accurate SPR/BLI small molecule screening. |
| Intracellular Degradation Validation | Lentivirus-mediated stable cell line tools to quantify PROTAC/molecular glue efficiency. |
| Cellular Knockdown Validation | Validated siRNA set with NC controls; lentivirus rescue vectors available for specificity confirmation. |
| Antiviral Screening (Influenza/HIV) | High-concentration protein stocks (mg/ml) for high-throughput SPR/BLI fragment screening. |
| Off-target Liability (TREX complex specificity) | THOC5, DDX39B, and eIF4A3 orthologs available for selectivity counter-screening. |
| Lack of Reliable Controls | Sequence-verified recombinant benchmark antibodies for robust assay calibration. |
Live ALY/ALYREF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Export Inhibitor Research
- ➤ Antiviral Mechanism Studies
- ➤ Latest Resistance Research (Cancer)
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ALY/ALYREF-targeting therapeutics is intensifying, with major players shifting focus from broad-spectrum nuclear export inhibitors (XPO1-based) to selective TREX complex disruption. As first-generation CRM1/XPO1 inhibitors face toxicity limitations, the next wave of R&D is targeting the ALYREF-NXF1 interaction interface for antiviral and oncologic applications. In oncology, ALYREF overexpression is heavily implicated in hepatocellular carcinoma, breast cancer, and glioblastoma, leading to interest in small molecule PPI inhibitors and targeted protein degraders (PROTACs). The emerging modality landscape favors small molecule protein-protein interaction (PPI) inhibitors, antisense oligonucleotides (ASOs), and molecular glues that can selectively dismantle the ALYREF-mediated RNA export complex without the systemic toxicity of older chemotherapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Antiviral Programs, Early Biotech | Influenza, Coronavirus, HIV; Hepatocellular Carcinoma, Solid Tumors | ALYREF-NXF1 binding assay (Need high-purity recombinant proteins with native folding); High-throughput screening for disruption tests |
| ASOs / siRNA (Export Blocking) | Ionis, Biogen (Platform), RNAi Therapeutics Companies | Neurodegeneration, Viral infections; Glioblastoma | Cellular export reporter assays (Need validated siRNA controls and ORF lentivirus); Knockdown validation (Need anti-ALYREF antibodies) |
| Targeted Protein Degraders (PROTACs) | Preclinical Innovators | Refractory Cancers | Degradation assays (Need lentivirus for stable ALYREF expression cell lines) |
| Molecular Glues | Proprietary Discovery Programs | Undruggable Cancers | Ternary complex formation (Need THOC5/DDX39B/eIF4A3 co-reagents) |
| Peptide Disruptors | Early Stage Biotechs | Solid Tumors | Domain mapping (Need RBD-specific fragments for epitope identification) |